Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SOFIVA GENOMICS CoROCO:6615 +1.77%68 Return-on-Tangible-Asset is 2.99% as of Jun. 2026, which is 52% below its 10-year median of 6.29. GuruFocus rates ROCO:6615 with a GF Score™ of 68/100 and a GF Value™ of NT$31.73 (Fairly Valued). The stock has 3 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, SOFIVA GENOMICS Co ranks better than 62.74% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. SOFIVA GENOMICS Co's annualizedNet Income for the quarter that ended in Jun. 2026 was NT$21.7 Mil. SOFIVA GENOMICS Co's average total tangible assets for the quarter that ended in Jun. 2026 was NT$725.7 Mil. Therefore, SOFIVA GENOMICS Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 2.99%.
The historical rank and industry rank for SOFIVA GENOMICS Co's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:6615'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.27 Med: 6.29 Max: 14.22
Current: 1.96
During the past 13 years, SOFIVA GENOMICS Co's highest Return-on-Tangible-Asset was 14.22%. The lowest was -1.27%. And the median was 6.29%.
ROCO:6615's Return-on-Tangible-Asset is ranked better than 62.74% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.02
vs ROCO:6615: 1.96
SOFIVA GENOMICS Co (ROCO:6615) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
SOFIVA GENOMICS Co Return-on-Tangible-Asset Related Terms
SOFIVA GENOMICS Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for SOFIVA GENOMICS Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6615 vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOFIVA GENOMICS Co Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where SOFIVA GENOMICS Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.99% mean?
SOFIVA GENOMICS Co (ROCO:6615) has a Return-on-Tangible-Asset of 2.99% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on SOFIVA GENOMICS Co and its competitors. This is 52% below median its historical median of 6.29. According to the industry distribution chart, SOFIVA GENOMICS Co ranks #79 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 37.3%.
Is SOFIVA GENOMICS Co's Return-on-Tangible-Asset too high?
SOFIVA GENOMICS Co's current Return-on-Tangible-Asset of 2.99% is 52% below median its 10-year median of 6.29. Based on the distribution chart, SOFIVA GENOMICS Co ranks #79 out of 212 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SOFIVA GENOMICS Co ranks #79 out of 212 companies for Return-on-Tangible-Asset. This puts SOFIVA GENOMICS Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on SOFIVA GENOMICS Co and its competitors. SOFIVA GENOMICS Co's current Return-on-Tangible-Asset is 2.99%, which is 52% below median its own 10-year median of 6.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.73, compared to a current price of NT$34.45 — trading 8.6% above its estimated fair value. The current Return-on-Tangible-Asset is 2.99%, which is 52% below median its 10-year median of 6.29. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current Return-on-Tangible-Asset is 2.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued.
The current stock price of NT$34.45 is trading 8.6% above its estimated GF Value™ of NT$31.73.
GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.
Key valuation signals for ROCO:6615:
Return-on-Tangible-Asset: 2.99% (52% below median its 10-year median of 6.29)
GF Value™: NT$31.73 vs. price of NT$34.45 (8.6% above fair value)
No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score
Get the complete analysis for ROCO:6615
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6615 has been successfully added to your 
